KNSA.US Kiniksa Pharmaceuticals Ltd

Healthcare Biotechnology USA Stocks
154.98 USD
Close of Nov 15, 2026
37.02 99.31
Market cap
USD 7.57B
P/E
73.0x
P/B
10.67x
ROE
17.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KNSA.US undervalued?

Graham number

The Graham number of Kiniksa Pharmaceuticals Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kiniksa Pharmaceuticals Ltd fundamental analysis

No fundamental analysis for Kiniksa Pharmaceuticals Ltd yet.

Kiniksa Pharmaceuticals Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, wh…

Full company profile